CSL has surged 35.5% since early June, clearing key moving averages despite little fundamental change. Is the battered biotech giant staging a comeback?

Mr Wilson’s interest rate outlook is central to his broader call. Falling energy prices, fading tariff-related inflation and ...

The parent of bankESB and TruNorth Bank will end its 157-year history as a depositor-owned institution, in part to fund the ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing ...

These stocks have jumped in the double- and triple-digits.

Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

The stock was up 39% to $2.25 in late Tuesday morning trading. The shares are now down less than 1% in the past 52 weeks. Farokhzad, who is also the biotechnology company's chair, made the unsolicited ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...